The cannabinoid receptor gene (CNR1) is not affected in German i.v. drug users

Addiction Biology

Volumn 6, Issue 2, 2001, Pages 183-187

  Heller, D ^a   Schneider, U ^a   Seifert, J ^a   Cimander, K F ^a   Stuhrmann, Manfred ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID RECEPTOR;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; DNA FLANKING REGION; DRUG DEPENDENCE; FEMALE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; GERMANY; HUMAN; MALE; NUCLEOTIDE REPEAT; OPIATE ADDICTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 17744374252     PISSN: 13556215     EISSN: None     Source Type: Journal    
DOI: 10.1080/13556210020040271     Document Type: Article

References (25)

1. 1. Herkenham M. Cannabinoid receptor localization in brain: relationship to motor and reward systems. Ann NY Acad Sci 1992;654:19-32.
2. 2. Howlett AC, Flemming RM. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 1984;26:532-8.
3. 3. Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA, 1992;89:3825-9.
4. 4. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-4.
5. 5. Gerard CM, Mollereau C, Vassart G, Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 1991;279:129-34.
6. 6. Dawson E. Identification of a polymorphic triplet repeat marker for the brain cannabinoid receptor gene: use in linkage and association studies. Psychiatr Genet 1995;5:S50.
7. 7. Caenazzo L, Hoehe MR, Hsieh W-T, Berrettini WH, Bonner TI, Gershon ES. HindIII identifies a two allele DNA polymorphism of the human cannabinoid receptor gene (CNR), Nucleic Acids Res 1991;19:4798.
8. 8. Gadzicki D, Müller-Vahl K, Sruhrmann M. A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. Mol Cell Probes 1999;13:321-3.
9. 9. Stuhrmann M, Gadzicki D, Müller-Vahl K. A mutation in the human cannabinoid receptor (CNR1) gene in patients with Gilles de laTourette syndrome. Am J Hum Genet 1999;65(suppl.): A44.
10. 10. Müller-Vahl K, Schneider U, Kolbe H, Emrich HM. Treatment of Tourette-syndrome with delta-9-tetrahydrocannabinol. Am J Psychiatry 1999;156: 495.
11. 11. Comings DE, Muhleman D, Gade R, et al. Cannabinoid receptor gene (CNR1): association with IV drug use. Mol Psychiatry 1997;2:161-8.
12. 12. Johnson JP, Muhleman D, MacMurray J, et al. Association between the cannabinoid receptor gene (CNR1), and the P300 event-related potential. Mol Psychiatry 1997;2:169-71.
13. 13. Tanda G, Pontieri FE, DiChiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common μ1 opioid receptor mechanism. Science 1997;276:2048-50.
14. 1 receptor knockout mice. Science 1999;283:401-4.
15. 15. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using polymerase chain reaction. Genomics 1989;5:874-9.
16. 16. Gambaro G, Anglani F, D'Angelo A, Association studies of genetic polymorphisms and complex disease. Lancet 2000;355:308-11.
17. 17. Li T, Liu X, Zhu ZH, et al. No association between (AAAT)n repeats in the cannabinoid receptor gene (CNR1) and heroin abuse in a Chinese population. Mol Psychiatry 2000;5:128-30.
18. 18. Stuhrmann M, Dörk T, Frühwirth M, et al. Detection of 100% of CFTR mutations in 63 CF-families from Tyrol. Clin Genet 1997;52:240-6.
19. 19. Jordanova A, Kalaydjieva L, Savov, A, et al. SSCP-analysis: a blind sensitivity trial. Hum Mutat 1997;10:65-70.
20. 20. DiChiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988;85:5274-8.
21. 21. Brigham J, Hering RI, Moss HB. Event-related potentials and alpha synchronization in preadolescent boys at risk for psychoactive substance use. Biol Psychiatrie 1995;37:834-46.
22. 22. Polich J. P300 in clinical applications: meaning; method, and measurement. Am J EEG Technique 1991;31:201-31.
23. 23. Comings DE, Muhleman D, Ahn C, Gysin R, Flanagan SD. The dopamine D2 receptor gene: a genetic risk factor in substance abuse. Drug Alcohol Depend 1994;34:175-80.
24. 24. Mailleux P, Vanderhaeghen JJ. Dopaminergic regulation of cannabinoid receptor: mRNA levels in the rat caudate-putamen: an in situ hybridization study. J Neurochem 1993;61:1705-12.
25. 25. Hershkowitz M, Goldman R, Raz A. Effect of cannabinoids on neurotransmitter uptake, ATPase activity and morphology of mouse brain synaptosomes. Biochemical Pharmacology, 1977;26: 1327-31.